Advanced or Unresectable Melanoma Progressing After PD1 Blockade

1 clinical trials · Condition

Record	Firm	Date
A Pilot Study of Sequential ONCOS-102, an Engineered Oncolytic Adenovirus Expressing GMCSF, and Pembrolizumab in Patients With Advanced or Unresectable Melanoma Progressing After Programmed Cell Death Protein 1 (PD1) Blockade (NCT03003676)	Targovax Oy	2016-12-01

Every clearance here is in the API, with alerts when new ones post.